Literature DB >> 9237482

Mutation analysis of chromosome 19 calmodulin (CALM3) gene in Alzheimer's disease patients.

D Ibarreta1, J Tao, R Parrilla, M S Ayuso.   

Abstract

The calcium buffering capacity of lymphoblasts from patients suffering of late onset Alzheimer's disease (AD) has been reported to be diminished. Calmodulin is a calcium binding protein codified by three genes, one of them (CALM3) maps to chromosome 19, nearby a gene, apoE, associated with late onset AD. In this study we screened for structural changes in the CALM3 gene from AD patients by PCR-SSCP analysis. We observed several point mutations in the intronic flanking regions of exons 3 and 4 of CALM 3 gene. However, we failed to detect any structural changes in the regions encoding the calcium binding domains of this gene. Similar results were obtained by RT-PCR analysis of CALM3 transcripts from AD patients carrying apoE epsilon4 allele. It is concluded that structural alterations in the CALM3 gene are not associated with the altered Ca2+ homeostasis shown by lymphoblasts from these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237482     DOI: 10.1016/s0304-3940(97)00453-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Increased APOE ε4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds.

Authors:  Anthony J Griswold; Katrina Celis; Parker L Bussies; Farid Rajabli; Patrice L Whitehead; Kara L Hamilton-Nelson; Gary W Beecham; Derek M Dykxhoorn; Karen Nuytemans; Liyong Wang; Olivia K Gardner; Daniel A Dorfsman; Eileen H Bigio; Marek Marsel Mesulam; Sandra Weintraub; Changiz Geula; Marla Gearing; Elisa McGrath-Martinez; Clifton L Dalgard; William K Scott; Jonathan L Haines; Margaret A Pericak-Vance; Juan I Young; Jeffery M Vance
Journal:  Alzheimers Dement       Date:  2021-02-01       Impact factor: 16.655

2.  Proteomic characterization of secretory granules in dopaminergic neurons indicates chromogranin/secretogranin-mediated protein processing impairment in Parkinson's disease.

Authors:  Gehua Wen; Hao Pang; Xu Wu; Enzhu Jiang; Xique Zhang; Xiaoni Zhan
Journal:  Aging (Albany NY)       Date:  2021-08-21       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.